国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2012年
20期
3020-3021
,共2页
功能性消化不良%幽门螺杆菌%临床疗效
功能性消化不良%幽門螺桿菌%臨床療效
공능성소화불량%유문라간균%림상료효
Functional dyspepsia%Helicobacter pylori%Clinical efficacy
目的 探讨Hp感染与FD的关系及根除HP治疗的疗效.方法 将138例FD患者分成治疗组和对照组,对照组给予促胃动力药物和抗抑郁药物治疗,治疗组在此基础上给予抗Hp药物治疗,观察两组患者治疗后Hp的根除率和临床疗效.结果 治疗结束后的1个月、6个月复查Hp根除率,治疗组患者2次复查后的根除率均为86.96％(60 69),对照组患者2次复查后的根除率均为0;治疗组的治愈+显效为86.95％,对照组为52.17％(P＜0.05);治疗期间两组不良反应程度均较轻,差异无显著性(P＞0.05).结论 Hp与功能性消化不良的关系有密切关系,采用抗Hp药物治疗功能性消化不良,临床效果显著.
目的 探討Hp感染與FD的關繫及根除HP治療的療效.方法 將138例FD患者分成治療組和對照組,對照組給予促胃動力藥物和抗抑鬱藥物治療,治療組在此基礎上給予抗Hp藥物治療,觀察兩組患者治療後Hp的根除率和臨床療效.結果 治療結束後的1箇月、6箇月複查Hp根除率,治療組患者2次複查後的根除率均為86.96％(60 69),對照組患者2次複查後的根除率均為0;治療組的治愈+顯效為86.95％,對照組為52.17％(P＜0.05);治療期間兩組不良反應程度均較輕,差異無顯著性(P＞0.05).結論 Hp與功能性消化不良的關繫有密切關繫,採用抗Hp藥物治療功能性消化不良,臨床效果顯著.
목적 탐토Hp감염여FD적관계급근제HP치료적료효.방법 장138례FD환자분성치료조화대조조,대조조급여촉위동력약물화항억욱약물치료,치료조재차기출상급여항Hp약물치료,관찰량조환자치료후Hp적근제솔화림상료효.결과 치료결속후적1개월、6개월복사Hp근제솔,치료조환자2차복사후적근제솔균위86.96％(60 69),대조조환자2차복사후적근제솔균위0;치료조적치유+현효위86.95％,대조조위52.17％(P＜0.05);치료기간량조불량반응정도균교경,차이무현저성(P＞0.05).결론 Hp여공능성소화불량적관계유밀절관계,채용항Hp약물치료공능성소화불량,림상효과현저.
Objective To discuss the relationship between helicobacter pylori (HP) and functional dyspepsia (FD) and efficacy of HP treatment.Methods 138 FD cases were divided into the treatment group and the control group.The control group was given the treatment of drugs to improve gastric power and anti-depressants,while the observation group given HP drugs additionally.HP's eradication rate and clinical efficacy of both groups were observed after treatment.Results As for HP' s eradication rate of one-month check and six-month check,the eradication rate of the treatment group after the two checks were both 86.96％,while those of the control group were both 0.The cure and actual effect of the treatment group was 86.95％,while that of the control group was 52.17 ％ (P＜ 0.05).During the treatment phase,the adverse effects of both groups were slight,with no significant difference(P＞ 0.05).Conclusions HP is closely related to FD.The treatment of FD with HP has significant clinical efficacy.
